Leqvio vs Losartan: Head-to-Head Efficacy Comparison

Why This Comparison Exists

Patients searching "Leqvio vs Losartan" are often managing multiple cardiometabolic risk factors at once, including elevated LDL cholesterol, high blood pressure, or both. Clinicians addressing total cardiovascular risk must decide which targets to treat, in what order, and with which agents. That is the real clinical question behind this search.

These two drugs do not compete for the same receptor, the same lab value, or the same slot in a treatment algorithm. Inclisiran (brand name Leqvio) silences PCSK9 production in the liver to reduce circulating LDL-C 1. Losartan blocks the angiotensin II type-1 receptor to lower blood pressure, reduce proteinuria, and provide end-organ protection 2. A patient with both hyperlipidemia and hypertension might use both drugs simultaneously rather than choosing one over the other.

Because no randomized controlled trial has ever compared inclisiran directly to losartan, every efficacy statement below is drawn from each drug's own key trials. Cross-trial comparisons carry inherent limitations: different patient populations, different endpoints, different follow-up durations. We present the data side by side but do not claim equivalence or superiority between them.

Mechanism of Action

Inclisiran and losartan work through fundamentally different biological pathways, and understanding each mechanism clarifies why combining them can make sense for high-risk patients.

Inclisiran is a small interfering RNA (siRNA) conjugated to a GalNAc ligand that targets hepatocytes specifically. Once inside the liver cell, it degrades the mRNA encoding proprotein convertase subtilisin/kexin type 9 (PCSK9). With less PCSK9 protein available, LDL receptors on the hepatocyte surface are recycled rather than destroyed, increasing LDL-C clearance from the bloodstream 1. The effect persists for approximately six months per injection because the siRNA remains active inside the hepatocyte through the RNA-induced silencing complex (RISC).

Losartan selectively blocks angiotensin II at the AT1 receptor. This prevents vasoconstriction, aldosterone secretion, and sympathetic activation. Blood pressure drops. Cardiac and renal remodeling slows. The LIFE study (N=9,193) demonstrated that losartan-based therapy reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% compared to atenolol-based therapy over a mean 4.8 years of follow-up, with a particularly pronounced 25% relative risk reduction in stroke 2.

The mechanisms are complementary. One addresses lipid burden. The other addresses hemodynamic stress and neurohormonal activation. Both contribute independently to atherosclerotic cardiovascular disease (ASCVD) progression.

Inclisiran Efficacy: The ORION Program

The pooled ORION-10 and ORION-11 trials enrolled 3,178 patients with ASCVD or ASCVD risk equivalents who had elevated LDL-C despite maximally tolerated statin therapy 1. ORION-10 (N=1,561) was conducted in the United States. ORION-11 (N=1,617) was conducted in Europe and South Africa.

At day 510 (approximately 17 months), inclisiran reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 versus placebo. The time-averaged reduction across all post-baseline measurements was 53.8% and 49.2%, respectively. These reductions were consistent across subgroups defined by age, sex, baseline LDL-C, statin intensity, and diabetes status.

Dosing was simple. Patients received 284 mg subcutaneous injections at day 1, day 90, and then every 6 months. Two shots a year after the loading phase. Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo, but most were mild and did not lead to discontinuation 1.

The ongoing ORION-4 outcomes trial (N=15,000, expected completion 2026) will determine whether this LDL-C reduction translates into fewer major adverse cardiovascular events (MACE). Until ORION-4 reports, the cardiovascular outcomes benefit of inclisiran is inferred from the established causal relationship between LDL-C lowering and ASCVD risk reduction, supported by Mendelian randomization studies and prior statin, ezetimibe, and PCSK9 monoclonal antibody trials 3.

Losartan Efficacy: The LIFE Trial and Beyond

The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial remains the largest outcomes study comparing losartan-based therapy against an active comparator in patients with hypertension and left ventricular hypertrophy (LVH) 2. Over a mean of 4.8 years, 9,193 patients were randomized to losartan-based or atenolol-based treatment.

The primary composite endpoint (cardiovascular death, MI, and stroke) occurred in 508 losartan patients versus 588 atenolol patients. That translates to a 13% relative risk reduction (adjusted hazard ratio 0.87 to 95% CI 0.77 to 0.98, P=0.021). Stroke alone was reduced by 25% (P=0.001). Blood pressure reductions were similar between groups, suggesting that losartan's cardiovascular benefit extends beyond blood pressure lowering alone.

A prespecified diabetic subgroup analysis (N=1,195) found an even larger 24% reduction in the primary composite endpoint with losartan-based therapy 4. Cardiovascular mortality dropped 37% and all-cause mortality dropped 39% in diabetic patients assigned to losartan. These results cemented losartan's position in guidelines for hypertensive patients with diabetes and LVH.

Losartan also has proven renal protection. The RENAAL trial (N=1,513) demonstrated a 16% reduction in the composite of doubling of serum creatinine, end-stage renal disease, or death in patients with type 2 diabetes and nephropathy 5. For patients with both hypertension and diabetic kidney disease, losartan carries a level of outcomes evidence that few antihypertensives match.

Dosing and Administration

The practical differences between these medications are substantial and influence adherence, cost, and patient experience.

Inclisiran requires in-office administration by a healthcare professional. The injection is subcutaneous, delivered to the abdomen. Year one involves three injections: baseline, 90 days, and 270 days. After that, patients return every six months. This schedule may improve adherence for patients who struggle with daily pills. A 2021 analysis found that real-world statin adherence drops below 50% by 12 months in many populations 6. A twice-yearly injection bypasses this problem entirely.

Losartan is taken orally, typically starting at 50 mg once daily, with titration to 100 mg daily based on blood pressure response. Some patients split the dose to twice daily for more consistent 24-hour coverage. Generic losartan is widely available and costs as little as $4 to $10 per month at most U.S. pharmacies.

The cost gap is stark. Inclisiran carries a wholesale acquisition cost of approximately $3,250 per injection ($6,500 per year after year one). Insurance coverage varies, and prior authorization is typically required. Losartan's annual cost is often under $120 for uninsured patients using generic formulations. This difference matters enormously when weighing treatment options, particularly for patients paying out of pocket.

Side Effect Profiles

Both drugs are well tolerated, but the adverse event patterns differ. Short sentences help here.

Inclisiran's most common side effect is injection-site reaction. This occurred in 5% of treated patients in ORION-10 and ORION-11, versus 0.7% with placebo. Reactions were typically mild erythema or pain at the injection site, resolving within days. Bronchitis, urinary tract infection, and back pain occurred at similar rates in inclisiran and placebo groups. No hepatotoxicity signal has emerged. Creatine kinase elevations were infrequent 1.

Losartan side effects include dizziness (especially during initial titration), hyperkalemia, and rare angioedema. Unlike ACE inhibitors, losartan does not cause dry cough, which is a frequent reason patients switch from drugs like lisinopril to an ARB. Losartan is absolutely contraindicated in pregnancy due to fetal toxicity, a black-box warning shared by all drugs acting on the renin-angiotensin system 7. Hyperkalemia risk increases when losartan is combined with potassium-sparing diuretics, potassium supplements, or other RAAS inhibitors.

Neither drug is considered high-risk for drug interactions in most patients, though clinicians should check renal function and potassium when initiating losartan, and liver function at baseline for inclisiran.

Who Is a Candidate for Each Drug

Patient selection depends on which cardiometabolic risk factor requires intervention. The distinction is straightforward.

Inclisiran is FDA-approved for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy. The typical candidate has already tried a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg), possibly with ezetimibe, and still has LDL-C above goal. The 2018 ACC/AHA cholesterol guidelines recommend a threshold of LDL-C 70 mg/dL or higher for very high-risk ASCVD patients to consider adding a non-statin agent 8.

Losartan is FDA-approved for hypertension, diabetic nephropathy in patients with type 2 diabetes and an elevated serum creatinine and proteinuria, and stroke risk reduction in hypertensive patients with LVH. The typical candidate has stage 1 or stage 2 hypertension and may have comorbid diabetes, chronic kidney disease, or LVH on echocardiogram.

Some patients need both drugs. A 62-year-old with type 2 diabetes, an LDL-C of 95 mg/dL on rosuvastatin 20 mg and ezetimibe, blood pressure of 148/92 mmHg, and microalbuminuria could reasonably receive losartan for blood pressure and renal protection while adding inclisiran for residual LDL-C burden. The drugs do not interact pharmacokinetically and address independent risk axes.

Can These Drugs Be Used Together

There is no pharmacokinetic interaction between inclisiran and losartan. Inclisiran is metabolized by nucleases in the liver, not by cytochrome P450 enzymes. Losartan is metabolized primarily by CYP2C9 and CYP3A4. Their metabolic pathways do not overlap.

From a clinical standpoint, combining a lipid-lowering agent with an antihypertensive is standard practice in cardiovascular risk management. The 2019 ACC/AHA primary prevention guidelines recommend treating both hypertension and hyperlipidemia when present, as their risks are additive 9. The Steno-2 trial demonstrated that multifactorial intervention targeting glucose, lipids, and blood pressure simultaneously reduced cardiovascular events by 53% compared to conventional treatment in patients with type 2 diabetes 10.

There is no clinical scenario where a physician would choose inclisiran instead of losartan for blood pressure control, or losartan instead of inclisiran for LDL-C reduction. They are not interchangeable. The "versus" framing reflects a search query, not a clinical decision.

Switching Between Inclisiran and Losartan

Switching from one to the other implies replacing one drug class with another, which is not clinically appropriate since they treat different conditions. If a patient stops inclisiran, LDL-C will rise back toward baseline over 3 to 6 months as PCSK9 production resumes. If a patient stops losartan, blood pressure will increase, and renal or cardiac protective effects will be lost.

A scenario where a patient discontinues one and starts the other would typically involve a change in diagnosis or clinical priorities. For example, a patient initially treated with losartan for hypertension who achieves blood pressure control through lifestyle changes might discontinue losartan but later develop hyperlipidemia requiring inclisiran. These are sequential clinical decisions, not a drug switch in the traditional sense.

According to the 2022 ACC Expert Consensus Decision Pathway, when adding non-statin therapies for LDL-C lowering, clinicians should ensure that existing antihypertensive regimens remain optimized rather than substituting one drug class for another 8.

Cost and Insurance Considerations

Generic losartan is one of the most affordable antihypertensives available. Most pharmacy benefit plans place it on the lowest formulary tier. Medicare Part D and Medicaid cover it without prior authorization. A 30-day supply of losartan 50 mg costs between $4 and $15 at major retail pharmacies.

Inclisiran's pricing is more complex. Novartis set the list price at $3,250 per dose. Medicare Part B covers inclisiran as a physician-administered drug (buy-and-bill), which means patients pay a 20% coinsurance after meeting their deductible unless they have supplemental coverage. Commercial plans vary widely. Some require prior authorization documenting statin intolerance or inadequate response. Novartis offers a patient assistance program for eligible uninsured or underinsured patients 11.

The cost-effectiveness of inclisiran depends heavily on baseline cardiovascular risk. An ICER analysis estimated the incremental cost-effectiveness ratio at approximately $92,000 per quality-adjusted life year (QALY) at list price, which falls near the commonly cited $100,000 to $150,000 per QALY willingness-to-pay threshold in the United States. If ORION-4 confirms hard outcomes benefits, this estimate will likely improve.

What the Guidelines Say

The American College of Cardiology, American Heart Association, and Endocrine Society each address LDL-C management and hypertension management in separate guideline documents, reflecting the distinct nature of these therapeutic targets.

For LDL-C: the 2018 ACC/AHA multisociety guideline recommends high-intensity statin therapy as first-line for ASCVD patients. If LDL-C remains at or above 70 mg/dL, ezetimibe is added. If LDL-C is still above goal, a PCSK9 inhibitor (evolocumab or alirocumab) or inclisiran may be considered 8. Inclisiran received FDA approval after the 2018 guideline was published, but the 2022 ACC Expert Consensus Decision Pathway explicitly includes it as a non-statin option.

For hypertension: the 2017 ACC/AHA hypertension guideline recommends initiating pharmacotherapy at blood pressure 130/80 mmHg or higher for patients with clinical CVD or 10-year ASCVD risk of 10% or more 12. ARBs like losartan are first-line agents, especially when the patient has diabetes, CKD, or heart failure with reduced ejection fraction. The guideline does not distinguish among individual ARBs, though losartan, valsartan, and irbesartan have the strongest outcomes trial support.

Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine, has noted: "The patients who benefit most from PCSK9-targeted therapies are those with the highest baseline LDL-C and the highest cardiovascular risk, where the absolute risk reduction justifies the intervention."

Dr. Suzanne Oparil, past president of the American Heart Association, emphasized in commentary on the LIFE trial: "Losartan's stroke reduction benefit beyond blood pressure lowering suggests direct vascular protective properties that distinguish it from older antihypertensives."

The Bottom Line on Efficacy

Comparing efficacy between inclisiran and losartan is like comparing insulin to metoprolol. Both reduce cardiovascular risk. They do so through entirely different mechanisms targeting entirely different risk factors.

Inclisiran delivers approximately 50% LDL-C reduction with twice-yearly dosing, and outcomes data from ORION-4 will clarify the magnitude of MACE reduction. Losartan delivers consistent blood pressure control with a 13% composite CV risk reduction (and 25% stroke reduction) proven in the LIFE trial over nearly five years.

The right question is not which drug is "better." The right question is which risk factor needs treatment. For patients carrying both risks, the answer may be both drugs, prescribed concurrently, each addressing its specific target with its specific evidence base. A fasting lipid panel with LDL-C above 70 mg/dL on maximally tolerated statin therapy warrants a PCSK9-targeted conversation. A blood pressure reading consistently above 130/80 mmHg warrants an antihypertensive conversation. Start with the numbers.